We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VOYAGER

News List

CyGenica gets $1.4 million funding from SOSV for cancer and rare genetic disease therapy expresspharma
June 09, 2021
Other investors participating in the round included the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io, and angel investors Sharaf Yamani and Sami Mikati.
Voyager Therapeutics, Sanofi Genzyme Restructure Gene Therapy Alliance contractpharma
June 18, 2019
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront.
Voyager Therapeutics poaches Genzyme, Sanofi executive Andre Turenne as new CEO fiercebiotech
July 09, 2018
Four months after Voyager Therapeutics’ chief and founder Steven Paul, M.D., said he would step down to become an “executive science adviser,” the neurological disease biotech has found a new leader.
Sanofi walks away from Voyager’s phase 2/3 Parkinson’s gene therapy biospectrumasia
November 02, 2017
Under Voyager’s Collaboration Agreement with Sanofi Genzyme, Sanofi Genzyme had an exclusive option for ex-U.S. development and commercial rights to VY-AADC